U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H21NO.ClH
Molecular Weight 291.816
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATOMOXETINE HYDROCHLORIDE

SMILES

Cl.CNCC[C@@H](OC1=C(C)C=CC=C1)C2=CC=CC=C2

InChI

InChIKey=LUCXVPAZUDVVBT-UNTBIKODSA-N
InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C17H21NO
Molecular Weight 255.3547
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/atomoxetine.html

Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter. Most common adverse reactions are: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence, constipation, dry mouth, dizziness, erectile dysfunction, and urinary hesitation. Atomoxetine is a substrate for CYP2D6 and hence concurrent treatment with CYP2D6 inhibitors such as bupropion (Wellbutrin) or fluoxetine (Prozac) is not recommended, as this can lead to significant elevations of plasma atomoxetine levels.

Originator

Curator's Comment: # Eli Lilly

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
STRATTERA

Approved Use

Attention-Deficit/Hyperactivity Disorder (ADHD) STRATTERA is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of STRATTERA Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see Clinical Studies (14)

Launch Date

1.03826883E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
414.82 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATOMOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2693.29 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATOMOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.64 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ATOMOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
ATOMOXETINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
unhealthy, 12 years
n = 1
Health Status: unhealthy
Condition: mistakenly instead of dextroampheta
Age Group: 12 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Tachycardia...
AEs leading to
discontinuation/dose reduction:
Tachycardia (1 patient)
Sources:
480 mg 1 times / day steady, oral
Highest studied dose
Dose: 480 mg, 1 times / day
Route: oral
Route: steady
Dose: 480 mg, 1 times / day
Sources:
unhealthy, 14 years
n = 1
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypertension (1 patient)
Sources:
2840 mg single, oral
Overdose
Dose: 2840 mg
Route: oral
Route: single
Dose: 2840 mg
Sources:
healthy, 17 years
n = 1
Health Status: healthy
Condition: attempted suicide
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Sinus tachycardia...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia (1 patient)
Sources:
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Co-administed with::
oxcarbazepine(36 g)
Quetiapine(9 mg)
Sources:
unknown, 19 years
n = 1
Health Status: unknown
Age Group: 19 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Depression central nervous system...
AEs leading to
discontinuation/dose reduction:
Depression central nervous system (1 patient)
Sources:
40 mg 2 times / day steady, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: steady
Dose: 40 mg, 2 times / day
Co-administed with::
fluoxetine
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Condition: temper outbursts, impulsivity, difficulty paying attention, marital discord
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Disc. AE: ST segment elevation myocardial infarction...
AEs leading to
discontinuation/dose reduction:
ST segment elevation myocardial infarction (1 patient)
Sources:
1.8 mg/kg 1 times / day steady, oral
Highest studied dose
Dose: 1.8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 1.8 mg/kg, 1 times / day
Sources:
unhealthy, 5 - 6 years
n = 44
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: 5 - 6 years
Sex: M+F
Population Size: 44
Sources:
120 mg 1 times / day steady, oral (max)
Studied dose
Dose: 120 mg, 1 times / day
Route: oral
Route: steady
Dose: 120 mg, 1 times / day
Sources:
unhealthy, adult
n = 45
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: adult
Sex: unknown
Population Size: 45
Sources:
Disc. AE: Nausea, Malaise...
AEs leading to
discontinuation/dose reduction:
Nausea (1 patient)
Malaise (1 patient)
Anorexia (1 patient)
Sources:
249 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 249 mg, 1 times / day
Route: oral
Route: steady
Dose: 249 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: children
Sex: M+F
Population Size: 40
Sources:
Other AEs: Drowsiness, Tachycardia...
Other AEs:
Drowsiness (10 patients)
Tachycardia (6 patients)
Nausea (3 patients)
Hypertension (2 patients)
Vomiting (2 patients)
Seizure (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Tachycardia 1 patient
Disc. AE
180 mg single, oral
Overdose
Dose: 180 mg
Route: oral
Route: single
Dose: 180 mg
Sources:
unhealthy, 12 years
n = 1
Health Status: unhealthy
Condition: mistakenly instead of dextroampheta
Age Group: 12 years
Sex: M
Population Size: 1
Sources:
Hypertension 1 patient
Disc. AE
480 mg 1 times / day steady, oral
Highest studied dose
Dose: 480 mg, 1 times / day
Route: oral
Route: steady
Dose: 480 mg, 1 times / day
Sources:
unhealthy, 14 years
n = 1
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Sinus tachycardia 1 patient
Disc. AE
2840 mg single, oral
Overdose
Dose: 2840 mg
Route: oral
Route: single
Dose: 2840 mg
Sources:
healthy, 17 years
n = 1
Health Status: healthy
Condition: attempted suicide
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Depression central nervous system 1 patient
Disc. AE
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Co-administed with::
oxcarbazepine(36 g)
Quetiapine(9 mg)
Sources:
unknown, 19 years
n = 1
Health Status: unknown
Age Group: 19 years
Sex: M
Population Size: 1
Sources:
ST segment elevation myocardial infarction 1 patient
Disc. AE
40 mg 2 times / day steady, oral
Recommended
Dose: 40 mg, 2 times / day
Route: oral
Route: steady
Dose: 40 mg, 2 times / day
Co-administed with::
fluoxetine
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Condition: temper outbursts, impulsivity, difficulty paying attention, marital discord
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Anorexia 1 patient
Disc. AE
120 mg 1 times / day steady, oral (max)
Studied dose
Dose: 120 mg, 1 times / day
Route: oral
Route: steady
Dose: 120 mg, 1 times / day
Sources:
unhealthy, adult
n = 45
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: adult
Sex: unknown
Population Size: 45
Sources:
Malaise 1 patient
Disc. AE
120 mg 1 times / day steady, oral (max)
Studied dose
Dose: 120 mg, 1 times / day
Route: oral
Route: steady
Dose: 120 mg, 1 times / day
Sources:
unhealthy, adult
n = 45
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: adult
Sex: unknown
Population Size: 45
Sources:
Nausea 1 patient
Disc. AE
120 mg 1 times / day steady, oral (max)
Studied dose
Dose: 120 mg, 1 times / day
Route: oral
Route: steady
Dose: 120 mg, 1 times / day
Sources:
unhealthy, adult
n = 45
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: adult
Sex: unknown
Population Size: 45
Sources:
Seizure 1 patient
249 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 249 mg, 1 times / day
Route: oral
Route: steady
Dose: 249 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: children
Sex: M+F
Population Size: 40
Sources:
Drowsiness 10 patients
249 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 249 mg, 1 times / day
Route: oral
Route: steady
Dose: 249 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: children
Sex: M+F
Population Size: 40
Sources:
Hypertension 2 patients
249 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 249 mg, 1 times / day
Route: oral
Route: steady
Dose: 249 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: children
Sex: M+F
Population Size: 40
Sources:
Vomiting 2 patients
249 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 249 mg, 1 times / day
Route: oral
Route: steady
Dose: 249 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: children
Sex: M+F
Population Size: 40
Sources:
Nausea 3 patients
249 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 249 mg, 1 times / day
Route: oral
Route: steady
Dose: 249 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: children
Sex: M+F
Population Size: 40
Sources:
Tachycardia 6 patients
249 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 249 mg, 1 times / day
Route: oral
Route: steady
Dose: 249 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: children
Sex: M+F
Population Size: 40
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no (co-administration study)
Comment: coadministration with desipramine did not alter the PK of desipramine
Page: 11, 28, 30
no
no (co-administration study)
Comment: coadministration with midazolam increased AUC by 15%
Page: 11, 28, 30
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: coadministration with paroxetine or fluoxetine increased atomoxetine steady-state plasma concentrations
Page: 8, 11, 22
unlikely
weak
weak
weak
weak
weak
weak
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder.
2002
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
2002
Drug development process for a product with a primary pediatric indication.
2002
Novel treatments for attention-deficit/hyperactivity disorder in children.
2002
Overview and neurobiology of attention-deficit/hyperactivity disorder.
2002
Castration increases nisoxetine-evoked norepinephrine levels in vivo within the olfactory bulb of male rats.
2002 Aug 9
Gateways to clinical trials.
2002 Dec
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
2002 Dec
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
2002 Dec
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
2002 Nov
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.
2002 Nov
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
2002 Nov
Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder.
2003
Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition.
2003 Feb
Atomoxetine (strattera) for ADHD.
2003 Feb 3
Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
2003 Jan
Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog.
2003 Jan
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.
2003 Jan 15
Strattera approved to treat ADHD.
2003 Mar-Apr
Gateways to clinical trials.
2003 May
The use of antidepressants to treat attention deficit hyperactivity disorder in adults.
2003 Sep
Non-stimulant medications in the treatment of ADHD.
2004
Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder.
2004
ADHD treatment across the life cycle.
2004
Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies.
2004 Aug
Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.
2004 Aug
Atomoxetine (Strattera) revisited.
2004 Aug 16
Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect.
2004 Aug 2
Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
2004 Feb
[Medical treatments of hyperactive child].
2004 Jan
Gateways to clinical trials.
2004 Jan-Feb
The use of atomoxetine adjunctively in fibromyalgia syndrome.
2004 Jul
New options in the pharmacological management of attention-deficit/hyperactivity disorder.
2004 Jul
Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action.
2004 Jul
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
2004 Jul
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
2004 Jul
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder.
2004 Jun
Acute oxcarbazepine and atomoxetine overdose with quetiapine.
2004 Jun
Pharmacological management of attention-deficit hyperactivity disorder.
2004 Jun
Atomoxetine--treatment of attention deficit hyperactivity disorder: beyond stimulants.
2004 May
New drugs for the treatment of attention-deficit/hyperactivity disorder.
2004 Nov
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication.
2004 Nov
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
2004 Nov 15
[Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
2004 Oct
Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder.
2004 Sep
Gateways to clinical trials.
2004 Sep
Atomoxetine and nonresponders to stimulants.
2004 Sep
Atomoxetine and tics in ADHD.
2004 Sep
Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine.
2004 Sep 6
Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.
2005 Apr
Patents

Sample Use Guides

In Vivo Use Guide
Atomoxetine should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day.
Route of Administration: Oral
Electrophysiological recordings was performed with the extracellular standard solution at different membrane potentials ranging from -80 mV to +40 mV while the concentration of the agonists (100 uM NMDA/10 uM glycine) and the antagonist (25 uM atomoxetine) were kept constant. The inhibitory effect was clearly voltage-dependent, so that the inhibition was attenuated by depolarization.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:34:54 UTC 2023
Edited
by admin
on Wed Jul 05 22:34:54 UTC 2023
Record UNII
57WVB6I2W0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATOMOXETINE HYDROCHLORIDE
JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   WHO-DD  
USAN  
Official Name English
NSC-759104
Code English
ATOMOXETINE HCL [VANDF]
Common Name English
(-)-N-METHYL-3-PHENYL-3-(O-TOLYLOXY)PROPYLAMINE HYDROCHLORIDE
Systematic Name English
ATOMOXETINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
ATOMOXETINE HCL
VANDF  
Common Name English
ATOMOXETINE HYDROCHLORIDE [USP-RS]
Common Name English
ATOMOXETINE HYDROCHLORIDE [JAN]
Common Name English
LY-139603
Code English
ATOMOXETINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
ATOMOXETINE (AS HYDROCHLORIDE)
Common Name English
TOMOXETINE HYDROCHLORIDE
Common Name English
Atomoxetine hydrochloride [WHO-DD]
Common Name English
ATOMOXETINE HYDROCHLORIDE [MI]
Common Name English
STRATTERA
Brand Name English
ATOMOXETINE HYDROCHLORIDE [MART.]
Common Name English
ATOMOXETINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BENZENEPROPANAMINE, N-METHYL-.GAMMA.-(2-METHYLPHENOXY)-, HYDROCHLORIDE, (-)
Common Name English
ATOMOXETINE HYDROCHLORIDE [USAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 173003
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
NCI_THESAURUS C265
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
Code System Code Type Description
DAILYMED
57WVB6I2W0
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
RXCUI
353103
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY RxNorm
CHEBI
331697
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
CAS
82248-59-7
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
NCI_THESAURUS
C47405
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
EVMPD
SUB75495
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
MERCK INDEX
M2124
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY Merck Index
NSC
759104
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL641
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
FDA UNII
57WVB6I2W0
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID2044266
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
DRUG BANK
DB00289
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
RS_ITEM_NUM
1044469
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
SMS_ID
100000137397
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
USAN
T-123
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
PUBCHEM
54840
Created by admin on Wed Jul 05 22:34:54 UTC 2023 , Edited by admin on Wed Jul 05 22:34:54 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY